Table 1 Comparison of pharmacological action of the delivered uricase with hyperuricemic blood models in vitro and in vivo.

From: Extracorporeal delivery of a therapeutic enzyme

System

Uricase dose (U)

TQa (μmole)

Ratio of maxSQ1i to TQ (3.3 h)

Ratio of maxSQ1i to TQ (6.0 h)

Initial rate for SQ1i (μmole/min)

In vitro

0.30 (6)

103 ± 19

0.88 ± 0.16

ND

0.78 ± 0.12

In vitro

0.75 (5)

155 ± 40

1.03 ± 0.18

ND

1.4 ± 0.3b

In vivo

0.75 (5)

136 ± 23

2.2 ± 0.7c

3.8 ± 1.2c

1.4 ± 0.4d

In vivo

1.5 (5)

203 ± 50

2.6 ± 0.9c

4.5 ± 1.6c

2.4 ± 0.8e

In vivo

2.3 (5)

153 ± 27

2.8 ± 0.3c

5.0 ± 0.6c

2.2 ± 0.5e

  1. ND: not determined; maxSQ1i: the maximum SQ1i after uricase action for the indicated period.
  2. aindicates the total blood capacity of 210 ml with hyperuricemia models in vitro and of 310 ml with models in vivo;
  3. bindicates P < 0.005 versus that with 0.3 U uricase in vitro;
  4. cindicates P < 0.001 versus all the data in vitro including those with 0.3 and 0.75 U uricase after the action for 3.3 h;
  5. dindicates P < 0.02 versus that with 0.30 U uricase in vitro while P > 0.9 versus that with 0.75 U uricase in vitro;
  6. eindicates P < 0.05 versus that with 0.75 U uricase in vivo and versus that with 0.75 U or 0.30 U uricase in vitro.
Back to article page